Compare · CNMD vs MDT
CNMD vs MDT
Side-by-side comparison of CONMED Corporation (CNMD) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CNMD and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $105.25B, about 94.7x CNMD ($1.11B).
- Over the past year, CNMD is down 37.9% and MDT is down 6.8% - MDT leads by 31.1 points.
- MDT has been more active in the news (22 items in the past 4 weeks vs 13 for CNMD).
- MDT has more recent analyst coverage (25 ratings vs 14 for CNMD).
- Company
- CONMED Corporation
- Medtronic plc.
- Price
- $36.92+7.00%
- $82.00+1.66%
- Market cap
- $1.11B
- $105.25B
- 1M return
- +0.50%
- +7.72%
- 1Y return
- -37.91%
- -6.80%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NYSE
- NYSE
- IPO
- 1987
- News (4w)
- 13
- 22
- Recent ratings
- 14
- 25
CONMED Corporation
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest CNMD
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Director Bronson David M. converted options into 668 shares, increasing direct ownership by 4% to 17,909 units (SEC Form 4)
- Director Council Laverne H converted options into 668 shares, increasing direct ownership by 17% to 4,716 units (SEC Form 4)
- SEC Form 4 filed by Director Kelderman Kim
- Director Farkas Charles converted options into 668 shares, increasing direct ownership by 4% to 15,527 units (SEC Form 4)
- Director Kaye Mark converted options into 668 shares, increasing direct ownership by 439% to 820 units (SEC Form 4)
- Director Schwarzentraub Barbara J converted options into 668 shares, increasing direct ownership by 15% to 5,012 units (SEC Form 4)
- Amendment: New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- New insider Lockwood Kimberly claimed ownership of 1,868 shares (SEC Form 3)
- CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
Latest MDT
- EVP & President Cardiovascular Kiil Harry Skip sold $336,965 worth of Ordinary Shares (4,189 units at $80.44), decreasing direct ownership by 10% to 37,227 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip covered exercise/tax liability with 6,817 units of Ordinary Shares, decreasing direct ownership by 14% to 41,416 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey covered exercise/tax liability with 41,936 units of Ordinary Shares, decreasing direct ownership by 12% to 301,163 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael covered exercise/tax liability with 7,471 units of Ordinary Shares, decreasing direct ownership by 11% to 63,122 units (SEC Form 4)
- SVP, Chief HR Officer Walter Matthew R. covered exercise/tax liability with 2,840 units of Ordinary Shares, decreasing direct ownership by 7% to 38,689 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. covered exercise/tax liability with 237 units of Ordinary Shares, decreasing direct ownership by 2% to 14,737 units (SEC Form 4)
- Medtronic upgraded by BTIG Research with a new price target
- Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
- Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
- Medtronic plc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits